FC
Therapeutic Areas
TAXIS Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TXA709 | MRSA infections | Phase 1 |
| Efflux Pump Inhibitors (EPIs) | Multidrug-resistant Gram-negative infections (e.g., Pseudomonas aeruginosa) | Preclinical |
| Dihydrofolate Reductase Inhibitors (DHFRIs) | Drug-resistant Gonorrhea | Preclinical |